Selective serotonin reuptake inhibitors vs placebo
Subjective sleep quality or quantity · adults with insomnia
1 finding from 1 review
- no estimate extracted3 studies · 135 participantsLow
Findings
What do systematic reviews say?
31 questions · 32 findings · 6 reviews
No studies found 3 · 9.4%GRADE not reported 3 · 9.4%Very low 19 · 59.4%Low 2 · 6.3%Moderate 5 · 15.6%High 0 · 0%
Selective serotonin reuptake inhibitors vs placebo
Other subjective measures of sleep (total sleep time, sleep onset latency, nocturnal awakenings and subjective sleep efficiency) (PSQI) (at 12 weeks) · adults with insomnia
1 finding from 1 review
- no estimate extracted1 study · 27 participantsVery low
Selective serotonin reuptake inhibitors vs placebo
Adverse events (at 12 weeks) · adults with insomnia
1 finding from 1 review
- no estimate extracted1 study · 27 participantsVery low
Selective serotonin reuptake inhibitors vs placebo
PSG sleep outcomes (at 12 weeks) · adults with insomnia
1 finding from 1 review
- no estimate extracted1 study · 60 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Dropout · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes study dropouts at 6‐12 weeks compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
- RR 0.81 [0.51, 1.3]2 studies · 64 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Adverse effects during antidepressant treatment period (0‐12 weeks) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes adverse effects during antidepressant treatment period (0‐12 weeks) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
- RR 1.05 [0.67, 1.64]1 study · 14 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Improvement in depression at 6‐12 weeks: HAM‐D score (continuous) · adults living with HIV and depression
1 finding from 1 review
- no estimate extracted1 study · 14 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: HAM‐D score (dichotomized) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
- RR 0.89 [0.54, 1.46]2 studies · 64 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) · adults living with HIV and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRI) changes improvement in depression at 6‐12 weeks: CGI‐I (score of 1 or 2) compared with tricyclic antidepressant (TCA) (very low certainty).
1 finding from 1 review
- RR 1.24 [0.68, 2.24]2 studies · 64 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Efficacy as a continuous outcome · patients with cancer and depression
1 finding from 1 review
- Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 237 participantsVery low
Selective serotonin reuptake inhibitors vs tricyclic antidepressants (TCAs)
Efficacy as a dichotomous outcome · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes efficacy as a dichotomous outcome compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
- Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes onlyRR 1.12 studies · 199 participantsVery low